ANI Pharmaceuticals to Present at September Investor Conferences

PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadership team, will participate in fireside chats at the following upcoming investor conferences:

   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Event 2026 Wells Fargo Healthcare Conference
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Date Thursday, September 10, 2026
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Time 1:30 p.m. ET
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Webcast Click here
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Event Morgan Stanley 24th Annual Global Healthcare Conference
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Date Monday, September 14, 2026
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Time 7:00 a.m. ET
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Webcast Click here
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Event H.C. Wainwright 28th Annual Global Investment Conference
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Date Tuesday, September 15, 2026
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Time 12.00 p.m. ET
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Webcast Click here
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

The live and archived webcasts will also be accessible from the Company’s website at www.anipharmaceuticals.com, in the Investors section under Events and Presentations.

About ANI

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit https://www.anipharmaceuticals.com.

Investor Relations:

Irina Koffler, Vice President, Investor Relations
T: 917-734-7387
E: [email protected]

Media Relations:

Argot Partners
T: 212-600-1494
E: [email protected]

SOURCE: ANI Pharmaceuticals, Inc.